Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
3.420
-0.150 (-4.20%)
At close: Aug 1, 2025, 4:00 PM
3.440
+0.020 (0.58%)
After-hours: Aug 1, 2025, 4:10 PM EDT
United States Steel Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
112
Market Cap
148.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 4 days ago - Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise - PRNewsWire
- 2 months ago - Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
- 2 months ago - Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 4 months ago - Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
- 5 months ago - Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PRNewsWire
- 6 months ago - KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PRNewsWire